PostEra
Medical chemistry powered by machine learning
- 21-100 employees
- Healthcare
- B2B
- Machine Learning
- MedTech
- North End, Boston, MA
Jump to section
Company mission
To accelerate the discover of new cures for patients.
Our take
PostEra is a biotechnology company using AI to help speed up the process of discovering new medicines. Its core platform, Proton, is designed to support medicinal chemistry by helping researchers design and optimize drug candidates more efficiently, with the goal of reducing the time and cost it takes to bring new treatments to patients.
The company works closely with major pharmaceutical partners to apply its technology to real-world drug development programs. It has also continued to build momentum through deeper collaboration with Pfizer, expanding both its existing AI Lab partnership and launching a new antibody-drug-conjugate (ADC) programme. The work centres on tis Proton platform, which is being used to accelerate and improve early-stage drug discover across both small molecules and more complex therapies.
This growing adoption highlights increasing confidence in PostEra's AI-driven approach to medicinal chemistry. With over $1B in partnership value across multiple biopharma collaborations and continues expansion of its pipelines, the company is ready to cement its place as a long-term player in AI-enabled drug development.
Steph
Company Specialist at Welcome to the Jungle
Funding (2 rounds)
Jan 2022
$24m
SERIES A
Mar 2020
$0.2m
SEED
Total funding: $24.2m
This company has top investors
Leadership
Aaron Morris
(Co-Founder & CEO)Prior to co-founding PostEra in 2019, Aaron spent over 5 years at Goldman Sachs as a Risk Analyst, Equity Derivatives Trader and ultimately as an Equity Trader.
Alpha Lee
(Co-Founder & CSO)Alpha is a Faculty Member at the University of Cambridge, a role they've held since 2017. Previously, they were a Scientific co-founder of Byterat.
Matt Robinson
(Co-Founder & CTO)Previously did research in Biomolecular Simulation and Machine Learning for Drug Discovery at Yale University and University of Cambridge, before co-founding PostEra.